Erratum: Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models (Human Molecular Genetics (2013) 22: 16 (3315-3328) DOI: 10.1093/hmg/ddt192);Nilotinib reverses loss of dopamine neurons and improvesmotorbehavior via autophagic degradation of α-synuclein in parkinson's disease models

Human Molecular Genetics

Volumn 22, Issue 16, 2013, Pages 3315-3328

  Hebron, Michaeline L ^a   Lonskaya, Irina ^a   Moussa, Charbel E H ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BAFILOMYCIN; COMPLEMENTARY DNA; DOPAMINE; HOMOVANILLIC ACID; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DISEASE; BRAIN LEVEL; CELL FRACTIONATION; CELL VACUOLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG TARGETING; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD AND DRUG ADMINISTRATION; GENE TRANSFER; LENTIVIRINAE; LOW DRUG DOSE; LYSOSOME; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84881250979     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddac274     Document Type: Erratum

References (69)

1. Benner, E.J., Banerjee, R., Reynolds, A.D., Sherman, S., Pisarev, V.M., Tsiperson, V., Nemachek, C., Ciborowski, P., Przedborski, S., Mosley, R.L. et al.. (2008) Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS ONE, 3, e1376.
2. Kuhn, D.M., Francescutti-Verbeem, D.M. and Thomas, D.M. (2006) Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Ann. N. Y. Acad. Sci., 1074, 31-41.
3. Reynolds, A.D., Kadiu, I., Garg, S.K., Glanzer, J.G., Nordgren, T., Ciborowski, P., Banerjee, R. and Gendelman, H.E. (2008) Nitrated alpha-synuclein and microglial neuroregulatory activities. J. Neuroimmune Pharmacol., 3, 59-74.
4. Goedert, M. (1999) Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philos. Trans. R. Soc. Lond. B Biol. Sci., 354, 1101-1118.
5. Goedert, M. (2001) Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci., 2, 492-501.
6. Lundvig, D., Lindersson, E. and Jensen, P.H. (2005) Pathogenic effects of alpha-synuclein aggregation. Brain. Res. Mol. Brain Res., 134, 3-17.
7. Spillantini, M.G., Crowther, R.A., Jakes, R., Cairns, N.J., Lantos, P.L. and Goedert, M. (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett., 251, 205-208.
8. Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M. and Goedert, M. (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA, 95, 6469-6473.
9. Spillantini, M.G. and Goedert, M. (2000) The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. N. Y. Acad. Sci., 920, 16-27.
10. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840.
11. Takeda, A., Hashimoto, M., Mallory, M., Sundsumo, M., Hansen, L. and Masliah, E. (2000) C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Acta Neuropathol., 99, 296-304.
12. Trojanowski, J.Q. and Lee, V.M. (2003) Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses. Ann. N. Y. Acad. Sci., 991, 107-110.
13. Wakabayashi, K., Matsumoto, K., Takayama, K., Yoshimoto, M. and Takahashi, H. (1997) NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci. Lett., 239, 45-48.
14. Imam, S.Z., Zhou, Q., Yamamoto, A., Valente, A.J., Ali, S.F., Bains, M., Roberts, J.L., Kahle, P.J., Clark, R.A. and Li, S. (2011) Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease. J. Neurosci., 31, 157-163.
15. Ko, H.S., Lee, Y., Shin, J.H., Karuppagounder, S.S., Gadad, B.S., Koleske, A.J., Pletnikova, O., Troncoso, J.C., Dawson, V.L. and Dawson, T.M. (2010) Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc. Natl Acad. Sci. USA, 107, 16691-16696.
16. Jing, Z., Caltagarone, J. and Bowser, R. (2009) Altered subcellular distribution of c-Abl in Alzheimer's disease. J. Alzheimers Dis., 17, 409-422.
17. Tremblay, M.A., Acker, C.M. and Davies, P. (2010) Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. J. Alzheimers Dis., 19, 721-733.
18. Wang, J.Y. (2000) Regulation of cell death by the Abl tyrosine kinase. Oncogene, 19, 5643-5650.
19. Schlatterer, S.D., Acker, C.M. and Davies, P. (2011) c-Abl in neurodegenerative disease. J. Mol. Neurosci., 45, 445-452.
20. Derkinderen, P., Scales, T.M., Hanger, D.P., Leung, K.Y., Byers, H.L., Ward, M.A., Lenz, C., Price, C., Bird, I.N., Perera, T. et al. (2005) Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J. Neurosci., 25, 6584-6593.
21. Schlatterer, S.D., Tremblay, M.A., Acker, C.M. and Davies, P. (2011) Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain. J. Alzheimers Dis., 25, 119-133.
22. Seglen, P.O. (1987) In: Glaumann, H. and Ballard, F.J. (eds.), Lysosomes: Their Role in Protein Breakdown. Academic Press, London, pp. 369-414.
23. de Duve, C. and Wattiaux, R. (1966) Functions of lysosomes. Annu. Rev. Physiol., 28, 435-492.
24. Dunn, W.A. Jr. (1994) Autophagy and related mechanisms of lysosome-mediated protein degradation. Trends Cell Biol., 4, 139-143.
25. Gordon, P.B. and Seglen, P.O. (1988) Prelysosomal convergence of autophagic and endocytic pathways. Biochem. Biophys. Res. Commun., 151, 40-47.
26. Boland, B., Kumar, A., Lee, S., Platt, F.M., Wegiel, J., Yu, W.H. and Nixon, R.A. (2008) Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J. Neurosci., 28, 6926-6937.
27. Kegel, K.B., Kim, M., Sapp, E., McIntyre, C., Castano, J.G., Aronin, N. and DiFiglia, M. (2000) Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J. Neurosci., 20, 7268-7278.
28. Nixon, R.A., Wegiel, J., Kumar, A., Yu, W.H., Peterhoff, C., Cataldo, A. and Cuervo, A.M. (2005) Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J. Neuropathol. Exp. Neurol., 64, 113-122.
29. Ravikumar, B., Duden, R. and Rubinsztein, D.C. (2002) Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet., 11, 1107-1117.
30. Sabatini, D.M. (2006) mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer, 6, 729-734.
31. Stefanis, L., Larsen, K.E., Rideout, H.J., Sulzer, D. and Greene, L.A. (2001) Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci., 21, 9549-9560.
32. Webb, J.L., Ravikumar, B., Atkins, J., Skepper, J.N. and Rubinsztein, D.C. (2003) Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem., 278, 25009-25013.
33. Lonskaya, I., Hebron, M.L., Algarzae, N.K., Desforges, N. and Moussa, C.E. (2012) Decreased parkin solubility is associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson's disease. Neuroscience, 232C, 90.
34. Winslow, A.R. and Rubinsztein, D.C. (2011) The Parkinson disease protein alpha-synuclein inhibits autophagy. Autophagy, 7, 429-431.
35. Winslow, A.R., Chen, C.W., Corrochano, S., Acevedo-Arozena, A., Gordon, D.E., Peden, A.A., Lichtenberg, M., Menzies, F.M., Ravikumar, B., Imarisio, S. et al. (2010) alpha-Synuclein impairs macroautophagy: implications for Parkinson's disease. J. Cell Biol., 190, 1023-1037.
36. Deremer, D.L., Ustun, C. and Natarajan, K. (2008) Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin. Ther., 30, 1956-1975.
37. Skorski, T. (2011) BCR-ABL1 kinase: hunting an elusive target with new weapons. Chem. Biol., 18, 1352-1353.
38. Mahon, F.X., Hayette, S., Lagarde, V., Belloc, F., Turcq, B., Nicolini, F., Belanger, C., Manley, P.W., Leroy, C., Etienne, G. et al. (2008) Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res., 68, 9809-9816.
39. Giasson, B.I., Duda, J.E., Quinn, S.M., Zhang, B., Trojanowski, J.Q. and Lee, V.M. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron, 34, 521-533.
40. Alvarez, A.R., Sandoval, P.C., Leal, N.R., Castro, P.U. and Kosik, K.S. (2004) Activation of the neuronal c-Abl tyrosine kinase by amyloid-beta-peptide and reactive oxygen species. Neurobiol. Dis., 17, 326-336.
41. Cancino, G.I., Toledo, E.M., Leal, N.R., Hernandez, D.E., Yevenes, L.F., Inestrosa, N.C. and Alvarez, A.R. (2008) STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's beta-amyloid deposits. Brain, 131, 2425-2442.
42. Salomoni, P. and Calabretta, B. (2009) Targeted therapies and autophagy: new insights from chronic myeloid leukemia. Autophagy, 5, 1050-1051.
43. Lonskaya, I., Shekoyan, A.R., Hebron, M.L., Desforges, N., Algarzae, N.K. and Moussa, C.E. (2013) Diminished parkin solubility and co-localization with intraneuronal amyloid-beta are associated with autophagic defects in Alzheimer's disease. J. Alzheimers Dis., 33, 231-247.
44. Klionsky, D.J., Elazar, Z., Seglen, P.O. and Rubinsztein, D.C. (2008) Does bafilomycin A1 block the fusion of autophagosomes with lysosomes?. Autophagy, 4, 849-950.
45. Danzer, K.M., Kranich, L.R., Ruf, W.P., Cagsal-Getkin, O., Winslow, A.R., Zhu, L., Vanderburg, C.R. and McLean, P.J. (2012) Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener., 7, 42.
46. Lundblad, M., Decressac, M., Mattsson, B. and Bjorklund, A. (2012) Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc. Natl Acad. Sci. USA, 109, 3213-3219.
47. Emmanouilidou, E., Elenis, D., Papasilekas, T., Stranjalis, G., Gerozissis, K., Ioannou, P.C. and Vekrellis, K. (2011) Assessment of alpha-synuclein secretion in mouse and human brain parenchyma. PLoS ONE, 6, e22225.
48. Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S.D., Ntzouni, M., Margaritis, L.H., Stefanis, L. and Vekrellis, K. (2010) Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci., 30, 6838-6851.
49. Lee, H.J., Patel, S. and Lee, S.J. (2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci., 25, 6016-6024.
50. Malkus, K.A. and Ischiropoulos, H. (2012) Regional deficiencies in chaperone-mediated autophagy underlie alpha-synuclein aggregation and neurodegeneration. Neurobiol. Dis., 46, 732-744.
51. Spencer, B., Potkar, R., Trejo, M., Rockenstein, E., Patrick, C., Gindi, R., Adame, A., Wyss-Coray, T. and Masliah, E. (2009) Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J. Neurosci., 29, 13578-13588.
52. Chu, C.T. (2006) Autophagic stress in neuronal injury and disease. J. Neuropathol. Exp. Neurol., 65, 423-432.
53. Recchia, A., Rota, D., Debetto, P., Peroni, D., Guidolin, D., Negro, A., Skaper, S.D. and Giusti, P. (2008) Generation of a alpha-synuclein-based rat model of Parkinson's disease. Neurobiol. Dis., 30, 8-18.
54. Bazzu, G., Calia, G., Puggioni, G., Spissu, Y., Rocchitta, G., Debetto, P., Grigoletto, J., Zusso, M., Migheli, R., Serra, P.A. et al. (2010) alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach. CNS Neurol. Disord. Drug Targets, 9, 482-490.
55. Thiruchelvam, M.J., Powers, J.M., Cory-Slechta, D.A. and Richfield, E.K. (2004) Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur. J. Neurosci., 19, 845-854.
56. McCormack, A.L., Mak, S.K., Henderson, J.M., Bumcrot, D., Farrer, M.J. and Di Monte, D.A. (2010) Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS ONE, 5, e12122.
57. Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T.E., Muzyczka, N., Mandel, R.J. and Bjorklund, A. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci., 22, 2780-2791.
58. Qiu, Z., Cang, Y. and Goff, S.P. (2010) c-Abl tyrosine kinase regulates cardiac growth and development. Proc. Natl Acad. Sci. USA, 107, 1136-1141.
59. Li, B., Boast, S., de los Santos, K., Schieren, I., Quiroz, M., Teitelbaum, S.L., Tondravi, M.M. and Goff, S.P. (2000) Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nat. Genet., 24, 304-308.
60. Schwartzberg, P.L., Stall, A.M., Hardin, J.D., Bowdish, K.S., Humaran, T., Boast, S., Harbison, M.L., Robertson, E.J. and Goff, S.P. (1991) Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell, 65, 1165-1175.
61. Tybulewicz, V.L., Crawford, C.E., Jackson, P.K., Bronson, R.T. and Mulligan, R.C. (1991) Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell, 65, 1153-1163.
62. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U. et al. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med., 346, 645-652.
63. Burns, M.P., Zhang, L., Rebeck, G.W., Querfurth, H.W. and Moussa, C.E. (2009) Parkin promotes intracellular Abeta1-42 clearance. Hum. Mol. Genet., 18, 3206-3216.
64. Herman, A.M. and Moussa, C.E. (2011) The ubiquitin ligase parkin modulates the execution of autophagy. Autophagy, 7, 919-921.
65. Khandelwal, P.J., Dumanis, S.B., Feng, L.R., Maguire-Zeiss, K., Rebeck, G., Lashuel, H.A. and Moussa, C.E. (2010) Parkinson-related parkin reduces alpha-Synuclein phosphorylation in a gene transfer model. Mol. Neurodegener., 5, 47.
66. Hebron, M.L., Lonskaya, I., Sharpe, K., Weerasinghe, P.P., Algarzae, N.K., Shekoyan, A.R. and Moussa, C.E. (2013) Parkin ubiquitinates Tar-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6). J. Biol. Chem., 288, 4103-4115.
67. Rebeck, G.W., Hoe, H.S. and Moussa, C.E. (2010) Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. J. Biol. Chem., 285, 7440-7446.
68. Khandelwal, P.J., Herman, A.M., Hoe, H.S., Rebeck, G.W. and Moussa, C.E. (2011) Parkin mediates beclin-dependent autophagic clearance of defective mitochondria and ubiquitinated Abeta in AD models. Hum. Mol. Genet., 20, 2091-2102.
69. Marzella, L., Ahlberg, J. and Glaumann, H. (1982) Isolation of autophagic vacuoles from rat liver: morphological and biochemical characterization. J. Cell. Biol., 93, 144-154.